Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
- Sponsor
- Federico II University
- Study ID
- NCT05430828
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Repatha (evolocumab); Praluent (alirocumab) — DRUGDosage form: Injection
Study Details
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.
Key Dates
- Start date
- Mar 7, 2020
- Status verified
- Jan 2026
- Primary completion
- Jan 30, 2022
- Completion
- Mar 31, 2030
Study Design
- Enrollment
- 5,000 participants (estimated)
Arms
- Arm: Group 1Subjects with hyperlipidaemia under PCSK9 inhibitors treatment (Repatha/Praulent).
Primary Outcome Measure
Description of adherence of treatment with PCSK9 inhibitors in a real-life Italian population. [ Time Frame: every 6 months ]
Central Contacts
- Pasquale Perrone Filardi, MD+390817462224
Related Studies
- Causes and Natural History of DyslipidemiasRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Alirocumab in Patients on a Stable Dialysis RegimenPHASE3 · Recruiting · Baylor Research Institute · Dallas, Texas
- Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders TrialPHASE2 · Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- Pharmacogenomic Informed Statin PrescribingRecruiting · VA Office of Research and Development · Indianapolis, Indiana